

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

Raji-Luc2

RRID:CVCL_C9CV

Type: Cell Line

Proper Citation

RRID:CVCL_C9CV

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_C9CV

Proper Citation: RRID:CVCL_C9CV

Description: Cell line Raji-Luc2 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: EBV-related Burkitt lymphoma

Comments: Characteristics: Stably expresses firefly luciferase under the control of the human EF1a promoter (ATCC=CCL-86-LUC2)., Population: African; Nigerian.

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: Raji-Luc2

Cross References: ATCC:CCL-86-LUC2, Wikidata:Q123033309

ID: CVCL_C9CV

Hierarchy: cvcl_0511

Record Creation Time: 20231016T223409+0000

Record Last Update: 20260905T183227+0000

Ratings and Alerts

No rating or validation information has been found for Raji-Luc2.

No alerts have been found for Raji-Luc2.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Cheng Z, et al. (2026) Structural dissection of CD38 antigen engagement by CAR binders and rational affinity tuning. iScience, 29(6), 115937.

Evangelista BA, et al. (2025) ALS-associated TDP-43 aggregates drive innate and adaptive immune cell activation. iScience, 28(6), 112648.

Deng Q, et al. (2024) SMARCA4 is a haploinsufficient B cell lymphoma tumor suppressor that fine-tunes centrocyte cell fate decisions. Cancer cell.

Cracchiolo MJ, et al. (2024) Comparable efficacy of oral bendamustine versus intravenous administration in treating hematologic malignancies. Cancer chemotherapy and pharmacology, 94(3), 361.